Procore signs multi-year strategic collaboration agreement with AWS
David Moatazedi, a director and officer at Evolus, Inc. (NASDAQ:EOLS), a healthcare company with a market capitalization of $841 million and impressive revenue growth of 32% in the last twelve months, recently sold a substantial portion of his holdings in the company. According to InvestingPro analysis, the company appears slightly undervalued at current levels, with strong financial health indicators including a healthy gross profit margin of 68%. On March 18, Moatazedi sold 103,376 shares of Evolus common stock at an average price of $13.255 per share, totaling approximately $1.37 million. The transaction was conducted under a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined plan to sell stocks. This sale was executed to cover tax withholding obligations related to the vesting of certain restricted stock units. The stock has shown strong momentum, delivering a 20% return year-to-date, while maintaining a comfortable liquidity position with a current ratio of 2.4. Following the transaction, Moatazedi retains direct ownership of 514,870 shares in the company. Want deeper insights into Evolus’s financial health and growth prospects? InvestingPro subscribers get access to 7 additional ProTips and comprehensive analysis through our exclusive Pro Research Report.
In other recent news, Evolus reported its fourth-quarter 2024 financial results, revealing a revenue of $79 million, which exceeded expectations, although its earnings per share (EPS) of -$0.11 fell short of the anticipated $0.02. The company achieved full-year revenues of $266.3 million, marking a 32% increase from the previous year. Evolus has projected its 2025 revenue to be between $345 million and $355 million, indicating a growth of 30% to 33%, driven in part by the early approval of new products Evolysse SMOOTH and FORM. Analysts from Stifel and H.C. Wainwright maintained their Buy ratings on Evolus stock, with price targets of $25 and $27, respectively, reflecting optimism about the company’s financial trajectory.
Evolus’s growth was supported by strong seasonal demand and increased market penetration, with over 50% of U.S. accounts now active and a record enrollment of 1.1 million participants in its loyalty programs. The company’s positive non-GAAP operating income of $0.3 million for 2024 was a significant milestone, achieved a year earlier than anticipated. With FDA approval of new products, Evolus expects to maintain its growth momentum and achieve operating profitability for the full fiscal year 2025. These developments position Evolus as a rapidly evolving player in the aesthetics market, with a strategy focused on expanding its product portfolio and market reach.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.